• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Long-Term Use of Topical Treatments in Atopic Dermatitis

Opinion
Video

Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.

Video content above is prompted by the following:

  • How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Related Videos
Related Content
Astrid Gast/AdobeStock

Elderly Atopic Dermatitis Cases Up 85% in the US Since 1990, New Study Shows

Sydney Jennings
April 23rd 2025
Article

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

Global Burden of Atopic Dermatitis in Older Adults Underestimated and Expected to Rise Substantially by 2050 / image credit ©Astrid Gast/stock.adobe.com

Global Burden of Atopic Dermatitis in Older Adults Underestimated and Expected to Rise Substantially by 2050

Grace Halsey
April 21st 2025
Article

The global prevalence of AD in older adults increased by 107% between 1990 and 2021, with a greater burden among women and in high sociodemographic regions.

Study Shows High Rate of Eczema Type Overlap: Daily Dose / image credit: ©New Africa/AdobeStock

Study Shows High Rate of Eczema Type Overlap: Daily Dose

Sydney Jennings
April 11th 2025
Article

Your daily dose of the clinical news you may have missed.

Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis / image credit ©Alphyn Biologics

Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis

Grace Halsey
April 8th 2025
Article

The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.

Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care are Persistent and Significant: New Scoping Review / image Peter Lio, MD

Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care are Persistent and Significant: New Scoping Review

Grace Halsey
April 7th 2025
Article

Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.

Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis

Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis

Grace Halsey
March 31st 2025
Article

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

© 2025 MJH Life Sciences

All rights reserved.